LadRx (LADX) EV-to-OCF: 0.11 (As of Aug. 25, 2026) — 75% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is LadRx EV-to-OCF?

LadRx LADX EV-to-OCF is 0.11 as of Aug. 25, 2026, which is 75% below its 10-year median of 0.44.

EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, LadRx's Enterprise Value is $-0.20 Mil. LadRx's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2025 was $-1.86 Mil. Therefore, LadRx's EV-to-OCF for today is 0.11.

The historical rank and industry rank for LadRx's EV-to-OCF or its related term are showing as below:

LADX' s EV-to-OCF Range Over the Past 10 Years
Min: -14.38   Med: 0.44   Max: 2.46
Current: 0.11

During the past 13 years, the highest EV-to-OCF of LadRx was 2.46. The lowest was -14.38. And the median was 0.44.

LADX's EV-to-OCF is not ranked
in the Biotechnology industry.
Industry Median: -3.63 vs LADX: 0.11

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-08-25), LadRx's stock price is $0.011. LadRx's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $-5.040. Therefore, LadRx's PE Ratio (TTM) for today is At Loss.


LadRx  (OTCPK:LADX) EV-to-OCF Explanation

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

LadRx's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.011/-5.040
=At Loss

LadRx's share price for today is $0.011.
LadRx's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.040.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.


LadRx EV-to-OCF Related Terms


LadRx EV-to-OCF Historical Data

* Premium members only.

The historical data trend for LadRx's EV-to-OCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LadRx EV-to-OCF Chart

LadRx Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-OCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.87 -1.40 -1.11 -1.37 -0.05

LadRx Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-OCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.51 -0.17 -0.29 -0.05 -0.32

LADX vs VRTX, REGN, ALNY: EV-to-OCF Comparison

For the Biotechnology subindustry, LadRx's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LadRx EV-to-OCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LadRx's EV-to-OCF distribution charts can be found below:

* The bar in red indicates where LadRx's EV-to-OCF falls into.



LadRx EV-to-OCF Calculation

LadRx's EV-to-OCF for today is calculated as:

EV-to-OCF=Enterprise Value (Today)/Cash Flow from Operations (TTM)
=-0.202/-1.858
=0.11

LadRx's current Enterprise Value is $-0.20 Mil.
LadRx's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.86 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EV-to-OCF →
What does a EV-to-OCF of 0.11 mean?
LadRx (LADX) has a EV-to-OCF of 0.11 as of Aug. 25, 2026. This is 75% below median its historical median of 0.44.
Is LadRx's EV-to-OCF too high?
LadRx's current EV-to-OCF of 0.11 is 75% below median its 10-year median of 0.44.
How does LadRx's EV-to-OCF compare to VRTX and REGN?
LadRx's EV-to-OCF of 0.11 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. LadRx's current EV-to-OCF is 0.11, which is 75% below median its own 10-year median of 0.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LadRx stock overvalued right now?
LadRx (LADX) has a current EV-to-OCF of 0.11. The current EV-to-OCF is 0.11, which is 75% below median its 10-year median of 0.44. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For LadRx (LADX), the current EV-to-OCF is 0.11 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LadRx Business Description

Address 11726 San Vicente Boulevard, Suite 650, Los Angeles, CA, USA, 90049
LadRx Corp operates as a biopharmaceutical research and development company in the healthcare sector of the United States. It is focused on the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company develops Aldoxorubicin, which is meant to cure soft tissue sarcoma, a kind of tumor. It also develops Arimoclomol which is in development in Niemann Pick disease Type C (NPC) and Gaucher disease.